Valeo Pharma Inc
TSX:VPH
Intrinsic Value
Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. [ Read More ]
The intrinsic value of one VPH stock under the Base Case scenario is 0.91 CAD. Compared to the current market price of 0.11 CAD, Valeo Pharma Inc is Undervalued by 88%.
Valuation Backtest
Valeo Pharma Inc
Run backtest to discover the historical profit from buying and selling VPH stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Valeo Pharma Inc
Current Assets | 25m |
Cash & Short-Term Investments | 9.6m |
Receivables | 5.1m |
Other Current Assets | 10.3m |
Non-Current Assets | 15.3m |
PP&E | 2.6m |
Intangibles | 12.7m |
Current Liabilities | 51.6m |
Accounts Payable | 15.8m |
Short-Term Debt | 26.4m |
Other Current Liabilities | 9.4m |
Non-Current Liabilities | 35.8m |
Long-Term Debt | 35m |
Other Non-Current Liabilities | 777k |
Earnings Waterfall
Valeo Pharma Inc
Revenue
|
54.3m
CAD
|
Cost of Revenue
|
-42.7m
CAD
|
Gross Profit
|
11.6m
CAD
|
Operating Expenses
|
-29.8m
CAD
|
Operating Income
|
-18.2m
CAD
|
Other Expenses
|
-10.2m
CAD
|
Net Income
|
-28.4m
CAD
|
Free Cash Flow Analysis
Valeo Pharma Inc
What is Free Cash Flow?
VPH Profitability Score
Profitability Due Diligence
Valeo Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Valeo Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
VPH Solvency Score
Solvency Due Diligence
Valeo Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Valeo Pharma Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VPH Price Targets Summary
Valeo Pharma Inc
According to Wall Street analysts, the average 1-year price target for VPH is 0.51 CAD with a low forecast of 0.4 CAD and a high forecast of 0.63 CAD.
Shareholder Return
VPH Price
Valeo Pharma Inc
Average Annual Return | 17.44% |
Standard Deviation of Annual Returns | 104.5% |
Max Drawdown | -94% |
Market Capitalization | 10.9m CAD |
Shares Outstanding | 98 657 400 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. The company is headquartered in Kirkland, Quebec and currently employs 100 full-time employees. The company went IPO on 2019-02-20. The firm acquires or in-licenses brand and hospital specialty products for sale in Canada. The firm is focused on four therapeutic areas, which includes respiratory, oncology, specialty products and neurology. Its respiratory product is Enerzair breezhaler and Atectura breezhaler; its oncology product is Yondelis; its specialty product includes Redesca, Ametop Gel, and M-Eslon and its neurology product is Onstryv. The firm has eight marketed brands and four additional products. Its wholly owned subsidiary is VPI Pharmaceuticals Inc.(VPI).
Contact
IPO
Employees
Officers
The intrinsic value of one VPH stock under the Base Case scenario is 0.91 CAD.
Compared to the current market price of 0.11 CAD, Valeo Pharma Inc is Undervalued by 88%.